Peter Alping

Statistics

Publications

Citations

1.4K

H-Index

Active since

2016

Affiliations

Karolinska Institutet(Current)

University of Gothenburg

Karolinska University Hospital

Kaiser Permanente

Umeå University

Peter Alping is an author at Karolinska Institutet specializing in relapsing-remitting multiple sclerosis treatment, multiple sclerosis, and multiple sclerosis pharmacotherapy.

ORCID

Publications per year

2016–2024

Publications

Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies

Gustavo Luna, Peter Alping, Joachim Burman et al. · JAMA Neurology · 2019 · 509 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +10

Rituximab in multiple sclerosis

Jonatan Salzer, Rasmus Svenningsson, Peter Alping et al. · Neurology · 2016 · 346 citations · Full text

Medicine, Neurology, Pharmacotherapy +14

Rituximab versus fingolimod after natalizumab in multiple sclerosis patients

Peter Alping, Thomas Frisell, Lenka Novakova et al. · Annals of Neurology · 2016 · 229 citations

Life Sciences, Neurology, Pharmacotherapy +16

Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients

Peter Alping, Johan Askling, Joachim Burman et al. · Annals of Neurology · 2020 · 136 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Validation of the Swedish Multiple Sclerosis Register

Peter Alping, Fredrik Piehl, Annette Langer‐Gould et al. · Epidemiology · 2018 · 64 citations · Full text

Public Health, Neurology, Clinical Epidemiology +11

1–5 of 10